Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03776071 · ClinicalTrials.gov registry record · Phase 3
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
A Phase 3 study of Glioblastoma, sponsored by Denovo Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT03776071 is a Phase 3 study of Glioblastoma that has completed, run by Denovo Biopharma. The registered enrollment target is 260 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (141% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03776071, a Phase 3 study of Glioblastoma, has completed, sponsored by Denovo Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Enzastaurin Hydrochloride
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine Health Chao Family Comprehensive Cancer Center - Orange
- The University of Southern California - Pasadena
- University of California San Francisco Helen Diller Family Comprehensive CA Ctr - San Francisco
Florida
- Lynn Cancer Institute - Boca Raton
- Mayo Clinic - Jacksonville - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
- Miami Cancer Institute - Miami
- Moffitt Cancer Center - Tampa
Arizona
- Barrow Neurological Institute - Phoenix
- Mayo Clinic - Arizona - Scottsdale
Colorado
- University of Colorado Hospital Anschutz Cancer Pavilion - Aurora
- Blue Sky Neurology - Englewood
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Smilow Cancer Hospital - New Haven - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03776071
The ClinicalTrials.gov registry entry for NCT03776071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (141% higher). The listed sponsor is Denovo Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03776071 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03776071 about?
NCT03776071 is a clinical study titled "A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1". This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
What is the current status of trial NCT03776071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2020-12-16. Estimated completion is 2024-02-29.
What conditions does trial NCT03776071 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03776071?
The interventions under investigation include: Placebo (OTHER), Temozolomide (DRUG), Radiotherapy (RADIATION), Enzastaurin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03776071?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03776071 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.